Congenital Abnormality
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Exploration of genotype-phenotype correlations suggests a trend toward milder phenotypes in patients with mutations predicted to cause haploinsufficiency of CDK13, while missense mutations affecting amino acid residue 842 appear most likely to be associated with structural malformations.
|
30904094 |
2019 |
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
It was shown that high expression of CDK12 and CDK13 but no cyclin K proteins is associated with worse overall survival among adenocarcinoma patients.
|
30535470 |
2019 |
Developmental Disabilities
|
0.010 |
Biomarker
|
group |
BEFREE |
Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13.
|
31440507 |
2019 |
Deglutition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Differential diagnosis and recommendations for clinical care of patients with CDK13-related disorder are also described, emphasizing baseline echocardiography, vigilance for feeding and swallowing difficulties, and regular developmental evaluation as key components of care.
|
30904094 |
2019 |
Congenital anomaly of brain
|
0.010 |
Biomarker
|
group |
BEFREE |
In this chapter, we review the 44 cases of CDK13-related disorder reported to date, highlighting key clinical pointers to this diagnosis including characteristic craniofacial features, feeding difficulties in infancy, and the presence of structural heart or brain malformations.
|
30904094 |
2019 |
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.
|
31668947 |
2019 |
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.
|
31668947 |
2019 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CDK13 RNA over-editing sites mediated by ADAR1 may serve as novel cancer driver events in HCC progression.
|
29996118 |
2018 |
Cardiac defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.
|
29222009 |
2018 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
CDK13 RNA over-editing sites mediated by ADAR1 may serve as novel cancer driver events in HCC progression.
|
29996118 |
2018 |
Abnormality of cardiovascular system morphology
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
De novo missense variants in CDK13 have been described as the cause of syndromic congenital heart defects in seven individuals ascertained from a large congenital cardiovascular malformations cohort.
|
28807008 |
2017 |
Refractory anemia with ringed sideroblasts
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RARS and RARS-T patient groups both consistently showed up-regulation of ALAS2 and down-regulation of ABCB7 in CD34+ cells, but several other genes were differentially expressed, including PSIP1 (LEDGF), CXCR4, and CDC2L5.
|
19692701 |
2009 |
Refractory anemia with ring sideroblasts associated with marked thrombocytosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RARS and RARS-T patient groups both consistently showed up-regulation of ALAS2 and down-regulation of ABCB7 in CD34+ cells, but several other genes were differentially expressed, including PSIP1 (LEDGF), CXCR4, and CDC2L5.
|
19692701 |
2009 |
Corneal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Autosomal recessive congenital hereditary endothelial dystrophy (AR-CHED or CHED2) is a bilateral corneal disorder manifesting at birth or in early childhood.
|
17679935 |
2007 |
Chandler syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Members of 16 families with autosomal recessive CHED were genotyped for 13 microsatellite markers at the CHED2 locus on chromosome 20p13-12.
|
16825429 |
2007 |
Congenital hereditary endothelial dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Autosomal recessive congenital hereditary endothelial dystrophy (AR-CHED or CHED2) is a bilateral corneal disorder manifesting at birth or in early childhood.
|
17679935 |
2007 |
CORNEAL ENDOTHELIAL DYSTROPHY 2
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Members of 16 families with autosomal recessive CHED were genotyped for 13 microsatellite markers at the CHED2 locus on chromosome 20p13-12.
|
16825429 |
2007 |
CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS
|
0.010 |
Biomarker
|
disease |
BEFREE |
A genotype study on six families with CDPD and on one family with either CHED or CDPD, from various ethnic backgrounds (in the seventh family, hearing loss could not be assessed because of the proband's young age), is reported here.
|
17220209 |
2007 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
|
9973934 |
1999 |
Congenital Heart Defects
|
0.020 |
GeneticVariation
|
group |
BEFREE |
De novo variants in the gene encoding cyclin-dependent kinase 13 (CDK13) have been associated with congenital heart defects and intellectual disability (ID).
|
29393965 |
2018 |
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Two editing sites (Q103R and K96R) in CDK13 showed significant over-editing in tumor, and these phenomenon were validated in 60 HCC patients.
|
29996118 |
2018 |
Congenital Heart Defects
|
0.020 |
Biomarker
|
group |
BEFREE |
Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.
|
28807008 |
2017 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Interestingly, the oncogenic activity of these genes (excluding FAM82B) was highly correlated with gene-copy numbers in tumor samples (correlation coefficient, r>0.423), indicating that amplifications of CENPF, GMNN, and CDK13 genes are tightly linked and coincident in tumors.
|
22912832 |
2012 |
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Therefore, it was revealed that LINC00152 contributed to the progression of HCC by the modulation of miR-215 and CDK13.
|
31297882 |
2019 |
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Two RNA editing sites from CDK13 were further validated in 60 HCC patients; and their potential regulatory mechanisms were investigated.
|
29996118 |
2018 |